Stifel Upgrades Globus Medical to Buy, Announces $61 Price Target
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Mathew Blackman has upgraded Globus Medical (NYSE:GMED) from Hold to Buy and announced a price target of $61.
September 19, 2023 | 7:55 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Globus Medical has been upgraded from Hold to Buy by Stifel with a price target of $61.
The upgrade from Hold to Buy by Stifel indicates a positive outlook for Globus Medical. The price target of $61 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100